The groundbreaking rise of Viagra has long been a example of pharmaceutical success, yet its legacy within the broader sector now triggers questions about potential gains. Alternative versions are eroding market share, prompting concerns that investing in companies heavily reliant to Viagra's once-dominant influence could be a speculative move , es